Learning Objectives

  • Understand the void filled by gene therapy in the treatment paradigm for transfusion-dependent β-thalassemia

  • Evaluate the appropriateness of gene therapy for individual patients with transfusion-dependent β-thalassemia

Case: The parent of a 12-year-old boy of Greek ancestry who has transfusion-dependent β-thalassemia are asking about curative options. He does not have any matched related donors, and a search through the international bone marrow donor registry has not identified a match either. He is transfused every 3 weeks to maintain a pretransfusion hemoglobin level of 9.5 to 10.5  g/dL and is well chelated, with a most recent liver magnetic resonance imaging showing a liver iron concentration of 3.4  mg/g dry weight and a cardiac T2* of 42  ms. The parents are concerned about school absences and their son's desire to participate in competitive sports as he gets older.

Transfusion-dependent β-thalassemia is...

1.
Christakopoulos
GE
,
Telange
R
,
Yen
J
,
Weiss
MJ.
Gene therapy and gene editing for β-thalassemia
.
Hematol Oncol Clin North Am
.
2023
;
37
(
2
):
433
-
447
.
doi:10.1016/j.hoc.2022.12.012
.
2.
Beaudoin
FL
,
Richardson
M
,
Synnott
PG
, et al.
Betibeglogene autotemcel for beta thalassemia: effectiveness and value; evidence report
.
Institute for Clinical and Economic Review
.
June
2
,
2022
. https://icer.org/beta-thalassemia-2022/#timeline
3.
Locatelli
F
,
Kwiatkowski
JL
,
Walters
MC
, et al.
Betibeglogene Autotemcel in Patients With Transfusion-Dependent β-Thalassemia: Updated Results From HGB-207 (Northstar-2) and HGB212 (Northstar-3)
.
European Hematology Association
.
2021
.
4.
Frangoul
H
,
Altshuler
D
,
Cappellini
MD
, et al.
CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia
.
N Engl J Med
.
2021
;
384
(
3
):
252
-
260
.
doi:10.1056/NEJMoa2031054
.
5.
Taher
AT
,
Weatherall
DJ
,
Cappellini
MD.
Thalassemia
.
Lancet
.
2018
;
391
(
10116
):
155
-
167
.
doi:10.1016/S0140-6736(17)31822-6
.
6.
Thompson
AA
,
Walters
MC
,
Kwiatkowski
J
, et al.
Gene therapy in patients with transfusion-dependent β-thalassemia
.
N Engl J Med
.
2018
;
378
:
1479
-
1493
.
doi:10.1056/NEJMoa1705342
.
7.
Li
C
,
Mathews
V
,
Kim
S
, et al.
Related and unrelated donor transplantation for β-thalassemia major: results of an international survey
.
Blood Adv
.
2019
;
3
(
17
):
2562
-
2570
.
doi:10.1182/bloodadvances.2019000291
.
8.
Thompson
AA
,
Locatelli
F
,
Yannaki
E
, et al.
Restoring iron homeostasis in pts who achieved transfusion independence after treatment with betibeglogene autotemcel gene therapy: results from up to 7 years of follow-up
.
Blood
.
2021
;
138
(
suppl 1
):
573
.
doi:10.1182/blood-2021-148177
.
9.
Boulad
F
,
Maggio
A
,
Wang
X
, et al.
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial
.
Nat Med
.
2022
;
28
:
63
-
70
.
doi:10.1038/s41591-021-01554-9
.
10.
Marktel
S
,
Scaramuzza
S
,
Cicalese
MP
, et al.
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia
.
Nat Med
.
2019
;
25
:
234
-
241
.
doi:10.1038/s41591-018-0301-6
.
You do not currently have access to this content.